Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.
A group of researchers has unearthed the secrets behind a tiny but crucial protein that shuttles zinc ions (Zn2+) within our bodies. The discovery offers a deeper understanding of how our cells maintain optimal health.
A researcher at the University of Central Florida College of Medicine has created a novel, more effective therapy for acute respiratory viral infections, a significant global cause of illness each year.
Researchers at NYU Grossman School of Medicine and Janssen Biotech, Inc. have shown in early tests that a bioengineered drug candidate can counter infection with Staphylococcus aureus – a bacterial species widely resistant to antibiotics and a major cause of death in hospitalized patients.
Numerous bacterium types have taken up residence in humans. Currently, research is concentrated on genetically modifying these bacteria to increase their inherent therapeutic qualities.
New research from Oregon Health & Science University and collaborators indicates lab-made antibodies may be able to cure people infected with yellow fever, a virus for which there is no treatment.
The constant evolution of new COVID-19 variants makes it critical for clinicians to have multiple therapies in their arsenal for treating drug-resistant infections. Researchers have now discovered that a new class of oral drugs that acts directly on human cells can inhibit a diverse range of pathogenic SARS-CoV-2 strains.
A tiny worm called the C. elegans is enabling scientists to explore the emerging theory that Parkinson's disease starts in the gut.
A new editorial was published in Genes & Cancer on January 19th, 2023, entitled, "Severe herpesvirus infection beats adult T-cell leukemia/lymphoma."
Prototype treatment for snake bite envenoming proves effective against the venom of African and Asian elapid snakes, such as some cobra, mamba, and krait species, new research shows.
Three years into the COVID-19 pandemic, new variant outbreaks continue to fuel economic disruptions and hospitalizations across the globe.
Researchers at the Department of Chemical Engineering, Indian Institute of Technology, India, have investigated the effects of oxidative stress on the production of monoclonal antibodies (mAbs), and how antioxidants can alleviate this stress to improve their performance.
Stem cells show particular promise in treating diseases for which few other effective treatments exist.
Using an approach based on CRISPR proteins, MIT researchers have developed a new way to precisely control the amount of a particular protein that is produced in mammalian cells.
A new COVID-19 antibody delivery approach has progressed to clinical trials, thanks to funding from the Defense Advanced Research Projects Agency (DARPA) and the Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND).
Can the SARS-CoV-2 vaccine reactivate previously suppressed antibody responses and pave the way for a unified coronavirus vaccine?
Funding will enable the development of Spirea’s pipeline of antibody drug conjugate therapeutics for the treatment of solid tumours.
Preclinical models that recapitulate aspects of human airway disease are essential for the advancement of novel therapeutics and vaccines.
In the early days of SARS-CoV-2 infection in the lungs, what happens at the single-cell level?
A folic acid-like drug, L-methylfolate, when administered alongside the standard therapy for patients with recurrent glioblastoma, changed aDNA process within their brain tumors, according to results from a phase 1 clinical trial.